Paragon 28, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full-Year Ended December 31, 2022
January 10, 2023 at 06:00 am EST
Share
Paragon 28, Inc. provided preliminary unaudited revenue guidance for the fourth quarter and full-year ended December 31, 2022. The company's preliminary unaudited net revenue for the fourth quarter of 2022 is expected to be in a range of $51.2 to $51.5 million, representing reported growth of approximately 20% compared to the fourth quarter of 2021.
The company's preliminary unaudited net revenue for the full-year of 2022 is expected to be in a range of $181.0 to $181.3 million, reflecting growth of approximately 23.0% compared to the full-year of 2021.
Paragon 28, Inc. is a medical device company focused on the foot and ankle orthopedic market. The Company provides orthopedic solutions, procedural approaches and instrumentation that cover a range of foot and ankle ailments, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. To treat these painful, debilitating or even life-threatening conditions, it provides a portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. Its broad suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. It has developed a comprehensive portfolio of foot and ankle surgical systems. Each system typically includes plates, screws, staples, nails, advanced joint and bone replacements, orthobiologics, and other implantation instruments and disposables specifically designed for the particular surgical system.
PARAGON 28, INC. 
